During the secondary analysis, the fewer conservative but clinically meaningful criterion of steady reaction (outlined like a fifty% or more reduction in MADRS from baseline for two months) was used. Of your patients who reached secure response, twenty five.8% within the esketamine group and fifty seven.6% in the placebo group https://mahatmav835baa6.wikisona.com/user